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1. Summary
Protein kinase ALK3/BMPR1Amediates bone morphogenetic protein (BMP) sig-
nalling through phosphorylation and activation of SMADs 1/5/8. SMAD6, a
transcriptional target of BMP, negatively regulates the BMP pathway by recruiting
E3 ubiquitin ligases and targeting ALK3 for ubiquitin-mediated degradation.
Here, we identify a deubiquitylating enzyme USP15 as an interactor of SMAD6
and ALK3. We show that USP15 enhances BMP-induced phosphorylation
of SMAD1 by interacting with and deubiquitylating ALK3. RNAi-mediated
depletion of USP15 increases ALK3 K48-linked polyubiquitylation, and redu-
ces both BMP-induced SMAD1 phosphorylation and transcription of BMP
target genes. We also show that loss of USP15 expression from mouse myoblast
cells inhibits BMP-induced osteoblast differentiation. Furthermore, USP15
modulates BMP-induced phosphorylation of SMAD1 and transcription during
Xenopus embryogenesis.
2. Introduction
Bone morphogenetic proteins (BMPs) are members of the transforming growth
factor beta (TGFb) family of cytokines. BMPs play crucial roles in embryogenesis
and tissue homeostasis. Aberrant BMP signalling is associated with develop-
mental defects as well as several human diseases [1–7]. BMPs signal through
phosphorylation and activation of type 1 BMP receptor kinases, including
ALK3/BMPR1A, which then phosphorylate intracellular SMAD transcrip-
tion factors 1, 5 and 8 at their C-terminal SXS motif [8,9]. Phosphorylation of
SMADs 1/5/8 induces their interaction with SMAD4 and translocation to the
nucleus, where along with other cofactors they regulate transcription [8,9].
Context-specific transcriptional programmes controlled by BMP signalling are
central to the regulation of cell differentiation, proliferation, apoptosis and
migration [10–12]. The action of BMPs in cells and tissues is therefore tightly regu-
lated at multiple steps of the BMP pathway. Together, a wide range of regulators
shape the action of BMP through key biological processes including the establish-
ment of the body axis and neuralization of the early embryo as well as
osteogenesis and bone formation in adults [2–4,11,13].
& 2014 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original
author and source are credited.
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Reversible ubiquitylation of multiple BMP pathway
components is one of the key mechanisms to dynamically
fine-tune BMP signalling [14]. The inhibitory SMADs 6 and
7, which are transcriptional targets of BMP signalling, are
part of a negative feedback loop regulating the pathway
[14–17]. SMAD6 selectively binds type I BMP receptor
ALK3, thereby limiting its ability to associate with and phos-
phorylate SMADs 1, 5 and 8 [18]. SMAD6 also recruits the E3
ubiquitin ligases SMURF1/2 to type I BMP receptors, targeting
them for ubiquitin-mediated degradation [15,19].
Polyubiquitin chains attached to target proteins can be
edited or removed by deubiquitylating enzymes (DUBs),
adding a further layer of control to signalling. DUBs that
target and remove ubiquitin chains from type I BMP recep-
tors have not yet been identified. However, several DUBs
have been implicated in the control of type I TGFb receptors.
For example, the closely related DUBs USP4, USP11 and
USP15 have been reported to modulate TGFb signalling by
deubiquitylating the type I TGFb receptor ALK5 [20–22].
USP15 has also been reported to act on monoubiquitylated
R-SMADs [23].
In the course of a proteomic approach to identify novel reg-
ulators of the BMP pathway, we identified USP11 and USP15
as SMAD6 interactors. Here, we demonstrate that USP15 inter-
acts with and deubiquitylates the type I BMP receptor ALK3.
Further work reveals USP15 as a key player in the BMP path-
way in human and mouse cells as well as Xenopus embryos,
influencing BMP-dependent SMAD1 phosphorylation, gene
transcription and osteoblastic differentiation.
3. Results
3.1. Identification of USP15 as an interactor of SMAD6
In an effort to uncover new regulators of the BMP pathway, we
employed a proteomic approach to identify interactors of
SMAD6. We stably integrated a single copy of GFP-tagged
SMAD6 into human embryonic kidney (HEK293) cells under a
tetracycline-inducible promoter. Treatment of these cells with
tetracycline resulted in a robust expression of GFP-SMAD6.
Immunoprecipitates (IPs) of GFP-SMAD6 from cell extracts
were resolved by SDS-PAGE and the interacting proteins were
excised, digested with trypsin and identified by mass spec-
trometry. Consistent with the reported roles of SMAD6 in
recruiting E3 ubiquitin ligases to ALK3 [14,17,19,24], we ident-
ified several members of the HECT E3 ubiquitin ligase family,
including SMURF2, WWP1/2, NEDD4L and ITCH, as interac-
tors of GFP-SMAD6 (figure 1a). Interestingly, two DUBs
(USP11 and USP15) were identified as novel interactors of
GFP-SMAD6 (figure 1a). USP11 and USP15 did not feature as
interactors of either GFP alone or of GFP-tagged SMADs 1–5
and 8 in similar proteomic assays [20,25]. Several other pro-
teins, including NASP, CTBP1/2, KPNA2, PIGR, PLUNC and
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Figure 1. Identification and characterization of USP15 as an interactor of SMAD6. (a) Coomassie stained gel image showing anti-GFP-IPs from HEK293 extracts
expressing GFP-SMAD6. The interacting proteins were excised as 2 mm gel pieces, digested with trypsin and identified by mass spectrometry. The location
where USP11 and USP15 were identified is indicated. All protein interactors of GFP-SMAD6 identified by mass spectrometry are indicated in the right panel. Protein
interactors of GFP control were removed from the list of GFP-SMAD6 interactors. (b) HEK293 cells were transfected transiently with FLAG-SMADs. Extract inputs were
resolved by SDS-PAGE and subjected to immunoblotting (IB) with anti-USP11, anti-USP15 and anti-FLAG antibodies as indicated. (c) FLAG-IPs were subjected to
immunoblotting with anti-USP11 and anti-FLAG antibodies. (d ) Endogenous pre-immune IgG or anti-USP15 IPs were subjected to immunoblotting with anti-FLAG
and anti-USP15 antibodies as indicated.
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LYZ were also identified as interactors of only GFP-SMAD6
(figure 1a).
We first investigated the specificity of interactions of SMAD6
with USP11 and USP15. To this end, an empty vector control or
FLAG-tagged SMADs 1, 3, 4, 6 and 7 were transiently trans-
fected into HEK293 cells (figure 1b). Endogenous USP11 was
detected predominantly in FLAG-SMAD6 and FLAG-SMAD7
IPs compared with IPs of other FLAG-SMADs (figure 1c).
When co-expressed in HEK293 cells, both FLAG-SMAD6
and FLAG-SMAD7 IPs pulled down HA-USP11 to a similar
extent (electronic supplementary material, figure S1). This con-
firms our previous observation that USP11 interacts with
SMAD7 [20].
To detect interactions between USP15 and FLAG-tagged
SMADs, endogenous USP15 was immunoprecipitated from
HEK293 cell extracts transfected with either empty vector
control or FLAG-tagged SMADs 1, 3, 4, 6 and 7 (figure 1b).
FLAG-SMAD6, but none of the other FLAG-SMADs, was
detected in USP15 IPs (figure 1d ), indicating the selective
nature of the interaction between SMAD6 and USP15. This
is consistent with our previous observations showing that
even under overexpression conditions, HA-USP15 does not
interact with FLAG-SMADs 1, 3, 4 and 7 [20].
Analysis of the expression of USP11 and USP15 in mouse
tissues showed that USP15 is expressed ubiquitously, whereas
USP11 was restricted to the brain, spleen, thymus and pan-
creas, with almost no observable expression elsewhere
(electronic supplementary material, figure S2).
3.2. Depletion of USP15 inhibits bone morphogenetic
protein pathway signalling
SMAD6 inhibits BMP signalling, in part, by recruiting E3 ubi-
quitin ligases to BMP receptors and targeting them for
ubiquitin-mediated degradation [14,15,18,19]. The association
of USP11 and USP15 with SMAD6 implied a possible role for
these DUBs in the BMP pathway. We have previously
reported that USP11, which interacts with both SMAD6 and
SMAD7, enhances TGFb signalling through ALK5 deubiqui-
tylation [20]. The selective nature of the interaction between
USP15 and SMAD6 prompted us to investigate a possible
role for USP15 in BMP signalling.
We therefore investigated the effect of RNAi-mediated
depletion of USP15 in BMP signalling in three different
human cell lines. Three distinct siRNAs targeting USP15 and a
control siRNA targeting FoxO4 were transfected in HEK293
cells (figure 2a), in which all three USP15 siRNAs caused an
approximately 80–90% reduction in USP15 protein levels com-
pared with the FoxO4 control (figure 2a). Depletion of USP15
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Figure 2. Depletion of USP15 inhibits BMP signalling. (a) HEK293 cells were transiently transfected with three individual siRNAs targeting USP15, serum-starved
overnight and stimulated with 6.25 ng ml21 BMP for 1 h prior to lysis. Extracts were resolved by SDS-PAGE and subjected to immunoblotting with antibodies
against endogenous USP15, pSMAD1, SMAD1 and GAPDH. (b) As in (a), except that siUSP15-3 was used to knockdown endogenous USP15 expression in HeLa
cells. (c) As in (b) except that U2OS cells were used. (d ) HEK293 cells were transiently transfected with siUSP15-3. Cells were serum-starved overnight and stimulated
with 6.25 ng ml21 BMP for 1 h. Cells were then washed and harvested 2 h later. The expression of USP15 and the BMP-target gene ID1 were assessed by qRT-PCR.
Results are average of six biological replicates. The error bars indicate s.d. (e) As in (d ), except that HEK293 cells were transfected with siUSP11. The expression of
USP11 and ID1 were assessed by qRT-PCR. Results are average of three biological replicates. The error bars indicate s.d.
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caused a substantial reduction in the levels of BMP-induced
pSMAD1 (tail-phosphorylated SMAD1) without significantly
affecting total SMAD1 levels (figure 2a). The inhibition of
BMP-induced pSMAD1 levels by siUSP15-3 was partially
rescued by the restoration of FLAG-USP15 overexpression in
cells (electronic supplementary material, figure S4).
In HeLa cervical cancer cells (figure 2b) and U2OS osteo-
sarcoma cells (figure 2c), transfection of siUSP15-3 caused
an almost complete loss of endogenous USP15 protein
expression. This caused a significant reduction in the levels of
BMP-induced pSMAD1, while the total SMAD1 levels were
not altered compared with siFoxO4 control (figure 2b,c).
We also investigated the effects of USP15 depletion on
BMP transcriptional activity in HEK293 cells. BMP induces
expression of the inhibitor of differentiation 1 (ID1) gene [26].
RNAi-mediated depletion of USP15 in HEK293 cells reduced
the expression of ID1 mRNA significantly in response to
BMP treatment compared with siFoxO4 control (figure 2d ).
By contrast, depletion of USP11, which inhibits TGFb-
dependent transcription [20], did not inhibit BMP-induced
expression of ID1 mRNA (figure 2e). Together our results
suggest that USP15 is critical for BMP-induced phosphoryl-
ation of SMAD1 and downstream transcriptional activity,
whereas USP11 is unlikely to affect BMP signalling. Consistent
with the reported role for USP15 in TGFb-dependent transcrip-
tion [21], we also found that depletion of USP15 from
TGFb-treated HaCaT cells resulted in a reduction of plasmino-
gen activator inhibitor 1 (PAI1) expression compared with
siFoxO4 control (electronic supplementary material, figure S3).
3.3. USP15 enhances bone morphogenetic protein
pathway signalling, and interacts and co-localizes
with ALK3
As depletion of USP15 inhibits BMP signalling, we asked
whether elevation of USP15 has the opposite effect. Indeed,
overexpression of HA-USP15 in HEK293 cells increased the
levels of pSMAD1 in response to BMP signalling (figure 3a),
and this was true in both nuclear [27–29] and cytoplasmic frac-
tions (figure 3b). Cytoplasmic fractions also contained the
majority of GFP-USP15 (figure 3b).
The enhanced BMP signalling due to USP15 overexpres-
sion suggests that SMAD6 itself is unlikely to be a substrate
of USP15; deubiquitylation and stabilization of SMAD6 by
USP15 would be expected to inhibit BMP signalling. The
observation that SMAD1 levels are unaffected by either
USP15 overexpression or depletion suggests that the target
of USP15 in the BMP pathway is upstream of SMAD1. The
type I BMP receptor ALK3 lies immediately upstream of
SMAD1 in the BMP pathway, and ALK3 is targeted for ubi-
quitylation by SMAD6 via recruitment of E3 ubiquitin ligases
[19]. We hypothesized that USP15 deubiquitylates ALK3,
thereby opposing the effect of SMAD6 and its associated E3
ubiquitin ligases.
To explore this idea, we first tested the ability of USP15 to
interactwithvariousALKs, includingALK3,upon co-expression
in HEK293 cells. GFP-USP15 IPs from HEK293 extracts inter-
acted with FLAG-ALK5, FLAG-ALK3, FLAG-ALK2 and
FLAG-ALK6 (figure 4a). Under these conditions, the associa-
tion between USP15 and ALK2 appeared to be the strongest
(figure 4a). Next, we tested how SMAD6 affected the interaction
betweenGFP-USP15 and FLAG-ALK3 (figure 4b). Expression of
SMAD6 caused a reduction in the ability of GFP-USP15 to inter-
act with FLAG-ALK3, suggesting that SMAD6 disrupts USP15 :
ALK3 association. Interestingly, the interaction between
GFP-USP15 and HA-SMAD6 was completely abolished
by FLAG-ALK3 overexpression (figure 4b), suggesting that
USP15 : SMAD6 and USP15 : ALK3 interactions could be
mutually exclusive.
In order to probe this possibility, we employed immuno-
fluorescence studies in U2OS osteosarcoma cells. In the
absence of SMAD6 or ALK3 overexpression, GFP-USP15
expression in U2OS cells was observed to be pan-cellular (elec-
tronic supplementary material, figure S5a). When HA-SMAD6
was co-expressed with GFP-USP15, SMAD6 was observed
mainly in the nucleus but also in the cytoplasm (electronic sup-
plementary material, figure S5b). There was a significant
overlap in expression between GFP-USP15 and HA-SMAD6
both in the nucleus and cytoplasm (electronic supplementary
material, figure S5b). When FLAG-ALK3 was co-expressed
with GFP-USP15, a significant GFP-USP15 fluorescence
was observed along cytoplasmic membranes, partially overlap-
ping with FLAG-ALK3 expression. FLAG-ALK3 expression
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Figure 3. USP15 augments BMP signalling. (a) HEK293 cells transiently expressing control HA-vector or HA-USP15 were serum-starved overnight and stimulated
with 6.25 ng ml21 BMP-2 for 1 h prior to lysis. Extracts were resolved by SDS-PAGE and subjected to immunoblotting with antibodies against HA, endogenous
pSMAD1, total SMAD1 and GAPDH. (b) HEK293 cells stably expressing GFP or GFP-USP15 were serum-starved overnight and stimulated with 6.25 ng ml21 BMP for
1 h prior to separation into cytoplasmic and nuclear fractions. The fractions were resolved by SDS-PAGE and subjected to immunoblotting with antibodies against
GFP, Lamin A/C, GAPDH, endogenous pSMAD1 and total SMAD1.
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was also observed along the cytoplasmic membranes, in the
cytoplasm and around the nuclear periphery (electronic
supplementary material, figure S5c). When GFP-USP15,
FLAG-ALK3 and HA-SMAD6 were all expressed together,
a partial reduction in the nuclear GFP-USP15 fluorescence
was observed (figure 4c; electronic supplementary material,
figure S5d,e). The enhanced cytoplasmic membrane fluor-
escence of GFP-USP15 as well as overall co-localization of
GFP-USP15 and FLAG-ALK3 was still observed (figure 4c).
Partial co-localization between HA-SMAD6 and FLAG-ALK3
as well as GFP-USP15 and HA-SMAD6 was also observed in
the cytoplasm (figure 4c). These results indicate that SMAD6
does not direct USP15 to ALK3 in the membrane. Rather,
expression of SMAD6 possibly modulates USP15 and/or
ALK3 in ways that potentially limit ALK3 access to USP15,
thereby disrupting the USP15 : ALK3 interaction.
3.4. USP15 deubiquitylates ALK3
The strong interaction between USP15 and ALK3 and their
co-localization at the plasma membrane suggested that
USP15 could act as a DUB for ALK3. Human recombinant
USP15 expressed in bacteria displays DUB activity in vitro
and is capable of cleaving not only K48-linked but also
K63- and K11-linked diubiquitin chains (figure 5a). It did
not cleave linear diubiquitin chain (figure 5a). To test whether
USP15 can deubiquitylate polyubiquitylated ALK3 in vitro,
we immunoprecipitated FLAG-ALK3 from HEK293 cells
treated with the proteasome inhibitor bortezomib (to enrich
the pool of polyubiquitylated FLAG-ALK3) and subjected
the FLAG-IPs to in vitro deubiquitylation by GST-USP15
(figure 5b). In the absence of USP15, FLAG-ALK3 IPs dis-
played robust polyubiquitylation, while the introduction of
(a)
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Figure 4. USP15 interacts and co-localizes with SMAD6 and ALK3. (a) HEK293 cells were transfected with GFP-USP15 with control vector or mammalian expression
vectors encoding N-terminal FLAG-tagged ALK5, ALK3, ALK2 or ALK6. Cells were lysed and extracts (1 mg) subjected to GFP-IPs. GFP-IPs (40%) or extract inputs
were resolved by SDS-PAGE and subjected to immunoblotting with the indicated antibodies. (b) HEK293 cells expressing GFP control or GFP-USP15 were transfected
with FLAG-ALK3, HA-SMAD6 or both as indicated. Cells were lysed and extracts (1 mg) subjected to GFP-IPs. GFP-IPs (40%) or extract inputs were resolved by SDS-
PAGE and subjected to immunoblotting with the indicated antibodies. (c) Fixed cell immunofluorescence was performed on U2OS cells transfected with FLAG-ALK3,
HA-SMAD6 and GFP-USP15. Individual and merged pictures are shown, indicating localization of FLAG-ALK3 mainly in the cytosol, HA-SMAD6 in the nucleus and
GFP-USP15 in both compartments. GFP-USP15 mainly co-localizes with FLAG-ALK3. Pictures were taken using a 60 lens, scale bar represents 30 mm.
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Figure 5. USP15 deubiquitylates ALK3. (a) Human recombinant GST-USP15 expressed in Escherichia coli was employed in an in vitro deubiquitylation assay using
K48-, K63- and K11-linked and linear di-ubiquitin (Ub) molecules as substrates. The reactions were quenched by adding SDS sample buffer and boiling for 5 min.
The samples were resolved by SDS-PAGE, Coomassie stained and then imaged. (b) HEK293 cell transfected with FLAG control or FLAG-ALK3 vectors were treated with
bortezomib (10 mM) for 3 h prior to lysis. FLAG-IPs from extracts (1 mg protein) were used as substrates for GST-USP15 in an in vitro deubiquitylation assay. The
reactions were stopped by adding SDS sample buffer and boiling for 5 min. The samples were resolved by SDS-PAGE and subjected to immunoblotting analysis using
the indicated antibodies. (c) HEK293 cells were transiently transfected with FLAG control or FLAG-ALK3 vectors with or without HA-USP15. Prior to lysis, cells were
treated with 10 mM bortezomib for 3 h. FLAG-IPs and extract inputs were resolved by SDS-PAGE and subjected to immunoblotting analysis using the indicated
antibodies. (d ) HEK293 cells transiently expressing FLAG-ALK3, HA-USP15 and USP15 C269S DUB dead mutant (DD) were serum-starved overnight, pretreated with
10 mM bortezomib for 3 h then stimulated with 6.25 ng ml– 1 BMP for 1 h prior to lysis. FLAG-IPs and extract inputs were resolved by SDS-PAGE and subjected to
immunoblotting with the indicated antibodies. (e) HEK293 cells transiently expressing siUSP15-3, FLAG-ALK3 and siUSP15-3 resistant silent mutant of HA-USP15
(HA-USP15R) were serum-starved overnight, pretreated with 10 mM bortezomib for 3 h then stimulated with 6.25 ng ml21 BMP for 1 h prior to lysis. FLAG-IPs and
extract inputs were resolved by SDS-PAGE and subjected to immunoblotting with the indicated antibodies.
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GST-USP15 caused efficient deubiquitylation, leading to the
accumulation of mono-ubiquitin (figure 5b).
We next asked whether USP15 can deubiquitylate ALK3
in cells. HEK293 cells were transfected with either a FLAG-
control vector or a vector encoding FLAG-ALK3 in the
presence or absence of HA-USP15 (figure 5c). In the absence
of HA-USP15, efficient K48-linked polyubiquitin and ubiquitin
chains were observed in FLAG-ALK3 IPs but not in control
FLAG-IPs (figure 5c). This polyubiquitylation does not
appear to require ALK3 kinase activity, as a catalytically inac-
tive ALK3-D380A mutant was polyubiquitylated to a similar
extent as the wild-type ALK3 (electronic supplementary
material, figure S6a). Both K48-linked polyubiquitin and
total ubiquitin chains were significantly reduced in FLAG-
ALK3 IPs from cells transfected with HA-USP15 (figure 5c).
Interestingly, the level of overall polyubiquitylation in extract
inputs was also reduced when wild-type HA-USP15 was
overexpressed (figure 5c).
To ask whether FLAG-ALK3 deubiquitylation requires
the deubiquitylase activity of USP15, we tested the ability
of a catalytically inactive mutant of USP15 (USP15[C269S];
USP15-DD) to deubiquitylate FLAG-ALK3 in HEK293 cells.
As described earlier, in the absence of HA-USP15 overexpres-
sion, FLAG-ALK3 IPs displayed robust polyubiquitylation,
particularly the K48-linked polyubiquitylation (figure 5d ).
The polyubiquitylation of FLAG-ALK3 was further con-
firmed in extracts by the observations of higher mobility
bands detected by anti-FLAG antibody immunoblotting
(figure 5d; FLAG-ALK3 long). Treatment of cells with BMP
did not alter the levels of FLAG-ALK3 polyubiquitylation
(figure 5d ). Overexpression of wild-type HA-USP15 but not
HA-USP15-DD resulted in almost complete loss of polyubi-
quitylation in FLAG-ALK3 IPs, indicating that the loss of
ubiquitylation in FLAG-ALK3 requires the deubiquitylase
activity of HA-USP15 (figure 5d ).
As noted earlier (figure 5c), the overall levels of poly-
ubiquitin chains in extracts were significantly reduced by
overexpression of wild-type HA-USP15 but were not affected
by HA-USP15-DD (figure 5d ). This global reduction caused
by overexpression of USP15 is consistent with its ability
to deubiquitylate multiple ubiquitin linkage types in vitro
(figure 5a). To establish a role for endogenous USP15 in
deubiquitylating ALK3, a loss-of function experiment was
performed (figure 5e). FLAG-ALK3 was transfected into
HEK293 cells in which endogenous USP15 was depleted
with siRNA. Depletion of endogenous USP15 led to an increase
in K48-linked polyubiquitylation in FLAG-ALK3 IPs as well
as in overall polyubiquitylation (figure 5e). This increased
polyubiquitylation was significantly inhibited when cells
were transfected with siRNA-resistant mutant of HA-USP15
(figure 5e), suggesting that the observed effects were unlikely
to be due to off-target effects of USP15 siRNA. Treatment of
cells with BMP had little effect on levels of FLAG-ALK3 poly-
ubiquitylation, indicating that USP15 regulates ALK3 levels
even under basal conditions (figure 5e).
3.5. Polyubiquitylated ALK3 undergoes proteasomal
degradation
Polyubiquitylation-dependent destruction of ALK3 in cells
could be mediated by the proteasomal or lysosomal degra-
dation pathways [30] or even both [31]. To test these
possibilities, we investigated the turnover of untagged
human ALK3 expressed in HEK293 cells in the presence of
the proteasomal inhibitor bortezomib and lysosomal fusion
inhibitor bafilomycin [25,32–34]. As expected, Bortezomib
resulted in the accumulation of polyubiquitin chains in
extracts, whereas bafilomycin yielded increased levels of
LC3-II [32] (figure 6a). Treatment of cells with bortezomib
resulted in enhanced levels of ALK3 compared with control,
whereas bafilomycin did not (figure 6a). Similarly, when cells
were treated with cycloheximide for 24 h prior to lysis to
prevent de novo ALK3 synthesis, bortezomib but not bafilo-
mycin resulted in enhanced levels of ALK3 compared with
control (figure 6a). Analogous results were obtained when
Xenopus ALK3-HA was expressed in HEK293 cells (electronic
supplementarymaterial, figure S6a). Consistently, the pretreat-
ment of cells with bortezomib but not bafilomycin resulted in
enhanced levels of polyubiquitylation in FLAG-ALK3 IPs
(electronic supplementary material, figure S6b). Together,
these results suggest that ALK3 polyubiquitylation leads to
its proteasomal degradation.
3.6. siUSP15-mediated inhibition of bone
morphogenetic protein signalling is rescued
by bortezomib and SMAD6 depletion
Depletion ofUSP15 inhibits BMP-inducedSMAD1phosphoryl-
ation and promotes K48-linked polyubiquitylation of ALK3
(figures 2a and 5e). If this depends upon polyubiquitylation-
mediated proteosomal degradation of ALK3, then proteasomal
inhibition predicted to stabilizeALK3 should rescue the effect of
USP15 depletion on BMP signalling. Consistent with this, pre-
treatment of HEK293 cells with the proteasomal inhibitor
bortezomib does indeed rescue BMP-induced pSMAD1 levels
reduced by USP15 depletion (figure 6b).
As discussed earlier, SMAD6 recruits the E3 ubiquitin
ligases that target ALK3 for polyubiquitin-mediated pro-
teasomal degradation [18]. We therefore asked whether
siRNA-mediated knockdown of SMAD6 was also able to
rescue the inhibition of BMP signalling caused by USP15
depletion. In HEK293 cells, the depletion of SMAD6 alone
resulted in enhanced phosphorylation of SMAD1 in response
to BMP signalling (figure 6c). More significantly, loss of
SMAD6 expression partially rescued the reduction in BMP-
induced pSMAD1 caused by USP15 depletion (figure 6c). In
the absence of antibodies to detect endogenous expression of
SMAD6, the SMAD6 knockdown was confirmed by qRT-PCR
(electronic supplementary material, figure S7).
3.7. USP15 knockdown inhibits alkaline
phosphatase activity
BMP signalling plays a key role in inducing myoblast pro-
genitor differentiation to the osteoblast lineage, as marked
by the acquisition of alkaline phosphatase activity [35]. We
investigated the effects of USP15 depletion on BMP-induced
SMAD1 phosphorylation and the development of alkaline
phosphatase activity in mouse myoblast C2C12 cells [26,35].
RNAi-mediated depletion of USP15 in C2C12 cells resulted
in a more than 90% reduction in USP15 protein expression
(figure 7a). Under these conditions, BMP-induced phos-
phorylation of SMAD1 was significantly reduced compared
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with controls (figure 7a), a reduction that was not due to a
decrease in total levels of SMAD1 (figure 7a). Loss of
USP15 significantly reduced BMP-induced alkaline phospha-
tase activity in C2C12 cells at both 48 h and 96 h post-BMP
stimulation (figure 7b).
3.8. USP15 impacts bone morphogenetic protein
signalling during Xenopus embryogenesis
BMP signalling plays a crucial role in dorsal–ventral patterning
during Xenopus development [3]. BMP-mediated phosphoryl-
ation of SMAD1 in Xenopus embryos is detected after stage 9
of development and is sustained thereafter [26]. We investi-
gated the role of USP15 on BMP signalling during Xenopus
embryogenesis. Injection of antisense morpholino oligonucleo-
tides targetingXenopusUSP15 (xUSP15-MO) into one-cell-stage
embryos caused no discernible change in the level of pSMAD1
at stage 8.5 but caused a significant reduction in pSMAD1 levels
at subsequent developmental stages (10 and 12.5) compared
with embryos injected with control morpholinos (control-MO;
figure 7c). However, the injection of xUSP15-MO did not
affect the stability of SMAD1 at any developmental stage
when compared with control-MO (electronic supplementary
material, figure S8a–c), suggesting that USP15 does not act
on SMAD1 directly but probably acts upstream of SMAD1.
Consistent with this, injection of one-cell-stage embryos with
xUSP15-MO resulted in the reduction of Xenopus ALK3 levels
over control (electronic supplementary material, figure S8d).
By contrast, overexpression of human USP15 resulted in the
stabilization of xALK3 (electronic supplementary material,
figure S8d). We also investigated the effect of USP15 on the
expression of the BMP marker xVENT1 in embryos. Animal
caps from embryos injected with either xUSP15-MO or con-
trol-MO were cut at stage 8.5, and then harvested for RNA at
stage 10. Injection of USP15-MO alone resulted in a significant
depletion of BMP-induced xVENT1 mRNA expression over
control (figure 7d).
4. Discussion
We show that USP15 interacts with SMAD6 and ALK3 and
enhances BMP signalling by deubiquitylating ALK3 and res-
cuing it from proteasomal destruction. Depletion of USP15
reduces BMP-induced phosphorylation of SMAD1 and the
transcription of BMP-target genes, as well as inhibiting the
differentiation of myoblasts into osteoblasts. Furthermore,
we demonstrate that ablation of USP15 expression from
Xenopus embryos results in the inhibition of BMP signalling
in vivo.
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Figure 6. ALK3 undergoes proteasomal degradation. (a) HEK293 cells transfected with untagged ALK3 were treated with or without 20 mM cycloheximide for 24 h
prior to lysis. Cells were treated with DMSO control, 100 nM bafilomycin A1 (to inhibit vacuolar-type Hþ ATPase) or 10 mM bortezomib (to inhibit the proteasome)
for 3 h prior to lysis. Extracts were resolved by SDS-PAGE and subjected to immunoblotting with the indicated antibodies. (b) HEK293 cells were transiently trans-
fected with siFoxO4 or siUSP15-3. Cells were serum-starved overnight, treated with or without 10 mM bortezomib for 3 h and then stimulated with or without
6.25 ng ml21 BMP for 1 h prior to lysis. Extracts were resolved by SDS-PAGE and subjected to immunoblotting with antibodies against endogenous USP15, pSMAD1
and total SMAD1. (c) HEK293 cells were transiently transfected with siFoxO4 (– ), siUSP15-3 or siSMAD6 as indicated. Twenty-four hours post siRNA transfection, cells
were serum-starved overnight and stimulated with or without 6.25 ng ml21 BMP for 1 h prior to lysis. Extracts were resolved by SDS-PAGE and subjected to
immunoblotting with antibodies against pSMAD1, total SMAD1, USP15 and GAPDH. The SMAD6 knockdown was confirmed by qRT-PCR (electronic supplementary
material, figure S7).
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4.1. Reversible ubiquitylation of type I receptors is
key to fine-tuning of bone morphogenetic
protein signalling
The regulation of ALK3 polyubiquitylation mediated by E3 ubi-
quitin ligases recruited by SMAD6 has been reported previously
[14,18]. Polyubiquitylation of certain receptor kinases, such as
EGFR, causes endocytosis-mediated degradation via the lyso-
some, which can be inhibited by bafilomycin A1, a potent
inhibitor of lysosomal acidification [33,36]. Our findings demon-
strate that bafilomycinA1 has no effect onALK3 turnover, while
the proteasome inhibitor bortezomib suppresses ALK3 degra-
dation. These results suggest that ALK3 turnover in cells is
controlledprimarily byproteasomal degradation. This is consist-
entwith ourobservations ofK48-linked ubiquitin chains, known
topromote proteasomal degradation, onALK3 IPs. Thepolyubi-
quitylation of ALK3 overexpressed in HEK293 cells was
unaffectedbyBMPstimulation for1 h.Because the accumulation
of SMAD6 and associated E3 ubiquitin ligases upon BMP treat-
ment takes substantially longer, it would be interesting to see
whether ALK3 polyubiquitylation is enhanced by a longer
course of BMP treatment. A catalytically inactive ALK3 mutant
overexpressed in HEK293 cells was polyubiquitylated to the
same extent as the wild-type, suggesting that the kinase activity
is not essential for ALK3 ubiquitylation.
Recent studies have highlighted the importance of
deubiquitylation of type I receptors in the dynamic fine-
tuning of the TGFb signalling pathway [14,17,20–23,25].
For example, the closely related DUBs USP4, USP11 and
USP15 have all been implicated in the control of TGFb signal-
ling through deubiquitylation of the type I TGFb receptor
ALK5 [20–22]. The DUBs that act on type I receptors in
the BMP pathway, however, have not been characterized.
Here, we demonstrate that USP15 enhances BMP signalling
by associating with and deubiquitylating the BMP type I
receptor ALK3. Moreover, we show that USP15 interacts
with other type I BMP receptors ALK2 and ALK6, as well
as TGFb receptor ALK5. Co-expression of FLAG-ALK3
and GFP-USP15 causes their co-localization, especially in
the plasma membrane. USP15 has also been reported to
bind to and deubiquitylate monoubiquitylated R-SMADs
to activate TGFb/BMP signalling [23]. However, we
were not able to detect an interaction between USP15 and
R-SMADs and, consistent with this, depletion or over-
expression of USP15 from human and mouse cells as well
as Xenopus embryos did not cause significant changes in
the levels of endogenous SMAD1.
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Figure 7. USP15 impacts osteoblastic differentiation in C2C12 myoblasts and modulates BMP signalling in Xenopus embryogenesis. (a) Mouse myoblast cell line
C2C12 were transfected with siRNAs targeting mouse FoxO4 or USP15. Cells were serum-starved overnight and treated with or without BMP for 1 h prior to lysis.
Extracts were resolved by SDS-PAGE and immunoblotted with antibodies against USP15, pSMAD1, total SMAD1 and GAPDH. (b) C2C12 cells transfected with mouse
siFoxO4 or mouse siUSP15 were grown for up to 4 days in the presence of BMP. Cells were lysed and the alkaline phosphatase activity measured using a fluorescence
plate reader. Data are represented as mean of three biological replicates and error bars indicate s.d. Representative extracts were resolved by SDS-PAGE and subjected
to immunoblotting with antibodies against USP15 and GAPDH. (c) Xenopus embryos were injected with 80 ng of either xUSP15- (xUSP15-MO) or control-MO
morpholinos at the one-cell stage and then collected at the indicated stages. Lysates were resolved by SDS-PAGE and immunoblotted with antibodies against
pSMAD1 and a-tubulin. (d ) qRT-PCR analysis of xVENT1 mRNA expression. Embryos were injected with 80 ng of either USP15-MO or control-MO at the one-cell
stage and then animal caps were cut at stage 8.5. The animal caps were collected at the equivalent embryo stage of 10.5 and processed for qRT-PCR.
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Among the DUBs, USP4, USP11 and USP15 are very simi-
lar, and they probably have similar cellular targets. Pathway
specificity is likely to be conferred by the relative affinities
with which they bind particular type I TGFb/BMP receptors
and/or I-SMADs, although it is likely that other factors are
important. We demonstrate that USP15 interacts with type I
BMP receptor ALKs 2, 3 and 6 as strongly as it binds to
type I TGFb receptor ALK5. SMAD6 overexpression disrupts
the association of USP15 with ALK3 and potently inhibits
BMP signalling. On the other hand, while SMAD6 also inter-
acts with USP11 strongly, depletion of USP11 did not inhibit
BMP signalling. Similarly, USP4 does not affect BMP signal-
ling [22]. The activity and substrate specificity of DUBs might
also be influenced by post-translational modifications within
DUBs or their targets [25], and differential expression of these
DUBs in cells and tissues could also contribute to the context-
dependent fine-tuning of TGFb/BMP signalling. Targeted
disruption of individual DUBs in mice might shed molecular
insights into the pathway-selective nature of USP4, USP11
and USP15.
4.2. USP15 impacts bone morphogenetic protein
signalling in multiple species
USP15 loss-of-function studies confirm that this DUB plays
a role in BMP signalling in several human and mouse cell
lines as well as Xenopus embryos. In human HEK293, HeLa
and U2OS cells, and in mouse C2C12 cells, RNAi-mediated
depletion ofUSP15 resulted in inhibition of BMP-induced phos-
phorylation of SMAD1. Depletion of USP15 fromHEK293 cells
caused a reduction in BMP-induced transcription, whereas
depletion of USP11 did not. Similarly, BMP-induced transcrip-
tion was unaffected following depletion of USP4 [22].
Reduction of USP15 expression from C2C12 myoblast cells
inhibited BMP-induced osteoblastic differentiation, as judged
by the reduction in alkaline phosphatase induction. Similarly,
loss of USP15 expression in Xenopus embryos led to the
reduction in pSMAD1 levels as well as the expression of
the ventral marker xVENT1. A genome wide loss-of-function
screen on all zebrafish deubiquitylases also identified USP15
as a critical player in dorsal–ventral patterning through the
BMP pathway [37].
4.3. USP15 as a potential target for the development of
inhibitors of bone morphogenetic protein and
transforming growth factor beta signalling
The beneficial roles for putative USP15 inhibitors against
TGFb signalling associated pathologies, such as glioblas-
toma, have been discussed previously [21]. Here, our
findings show that USP15 DUB activity is essential for BMP
signalling, and that loss of USP15 function inhibits BMP sig-
nalling in human and mouse cells, as well as during Xenopus
embryogenesis. Mutations leading to overactive BMP signal-
ling are associated with diseases such as heterotopic
ossification, Duchenne muscular dystrophy and bone metas-
tasis [6,38]. Moreover, high alkaline phosphatase activity is
linked to poor prognosis in patients with prostatic bone
metastases [38], and we found that loss of USP15 inhibited
BMP-induced alkaline phosphatase activity in C2C12 cells.
Inhibition of USP15 might therefore be employed as a
strategy to inhibit BMP signalling. However, as would be
expected for any DUB, USP15 has multiple other reported
targets [39–43] and is likely to have many more; hence
USP15 inhibitors will be predicted to be non-selective and
affect many cellular processes beyond those controlled by
BMP/TGFb signals.
5. Material and methods
5.1. Antibodies
Antibodies against USP11, USP15 and SMAD1 were raised in
sheep using GST-tagged proteins as antigens and affinity pur-
ified. Anti-SMAD1 antibody for use with Xenopus extracts was
from Santa Cruz Biotechnology. Antibody against ALK3 was
raised in sheep using His-ALK3(aa200-end) as an antigen
and affinity purified. Anti-HA-HRP antibody and anti-a
tubulin were from Sigma. Antibodies against phospho-
SMAD1/5 (Ser463/465) and 8 (Ser426/428), GAPDH, b-actin
and Lamin A/C were from Cell Signaling Technology. Anti-
ubiquitin antibody was from Dako. Goat anti-rabbit, mouse
and sheep HRP conjugated antibodies were from Pierce.
Goat anti-mouse and anti-rabbit IRDye 680LT and 800CW
coupled antibodies were from Li-Cor.
5.2. Plasmids
Mammalian expression constructs encoding human USP11,
USP15, ALK2, ALK3, ALK3[D380A], ALK5, ALK6, SMAD1,
2, 3, 4, 6 and 7 were cloned into pCMV5 or pCDNA-Frt-TO
(Invitrogen) vectors with or without N-terminal 3xFLAG,
HA and GFP-tags. pCDNA-Frt-TO plasmids were used to
generate stable tetracycline-inducible HEK293 cell lines fol-
lowing the manufacturer’s protocol (Invitrogen). All DNA
constructs used were verified by DNA sequencing, per-
formed by DNA Sequencing & Services (MRCPPU, College
of Life Sciences, University of Dundee, UK, www.dnaseq.
co.uk) using Applied Biosystems Big-Dye v. 3.1 chemistry
on an Applied Biosystems model 3730 automated capillary
DNA sequencer. Xenopus ALK3 (xALK3-HA) was con-
structed by inserting the 3xHA tag 30 to the ALK3 signal
sequence by PCR using the pSP64TBMPR plasmid as a tem-
plate (Addgene #15068) [44] with the following primers:
(Forward: GTACCTGACTATGCATACCCTTATGATGTACC
AGACTACGCTCAGGACTTTAACATCTTGCCACACAGAAC;
reverse: GTCATAAGGATAAGCGTAATCTGGAACATCGT
ATGGGTATCCTTGGGTATGAATAACAAGCAGTAAG). The
resulting PCR product was phosphorylated with polynucleo-
tide kinase and then ligated with DNA ligase followed by
DpnI digest.
5.3. Cell culture, transfection and lysis
Cells were propagated in DMEM media (Gibco) supplemen-
ted with 10% FBS (Hyclone), 1% penicillin/streptomycin
(Gibco) and 2 mM L-glutamine. Cells were kept at 378C in a
humidified incubatorwith 5%CO2. Cell lines stably expressing
tetracycline-inducible GFP-tagged proteins were grown in
media that additionally contained 100 mg ml21 hygromycin
and 15 mg ml21 blasticidin. Human embryonic kidney
(HEK293) cells were transfected with appropriate constructs
(2 mg of each plasmid per 10-cm diameter dish) using
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polyethyleneimine (PEI; Polysciences) as described previously
[45]. For siRNA transfections, Transfectin reagent (Bio-Rad)
was used following the manufacturer’s protocol. Unless indi-
cated otherwise, cells were treated with 6.25 ng ml21 BMP-2
for 1 h, 100 nM bafilomycin A1 for 3 h, 10 mM bortezomib
for 3 h or control solvents prior to lysis. For protein appli-
cations, cells were scraped directly into cell lysis buffer
(50 mM Tris–HCl pH 7.5, 1 mM EGTA, 1 mM EDTA, 1%
Triton X-100, 1 mM activated sodium orthovanadate, 50 mM
sodium flouride, 5 mM sodium pyrophosphate, 0.27 M
sucrose, 5 mM b-glycerophosphate, 0.1% b-mercaptoethanol
and 1 tablet of protease inhibitor cocktail (Roche) per 25 ml)
and snap frozen in liquid nitrogen. For RNA applications,
cells were processed using an RNA extraction kit (Qiagen)
according to the manufacturer’s instructions.
5.4. Xenopus maintenance and manipulation
Xenopus embryos were obtained by in vitro fertilization and
staged according to Nieuwkoop & Faber [46]. Lissamine
coupled USP15 (xUSP15-MO) and control antisense morpho-
lino (control-MO) oligonucleotides [23] were obtained from
GeneTools (Philomath, OR, USA). These were dissolved in
distilled water and stored at 48C. Sequences were as follows:
xUSP15-MO: 50-CGCCCTCCGCCATCTTACTCACTT-30 Lis-
samine; control-MO 50-CCTCTTACCTCAGTTACAATTTA
TA-30 Lissamine. Animal cap assays were carried out as
described previously [47].
5.5. Immunoprecipitation and immunoblotting
Snap frozen cell extracts were allowed to thaw on ice and cen-
trifuged at 17 500g for 10 min at 48C. Protein concentrationwas
determined spectrophotometrically using Bradford reagent
(Thermo Scientific). Extracts (1 mg) were then subjected to
immunoprecipitation with 10 ml packed beads (GFP-Trap
(Chromatek), anti-FLAG M2 gel (Sigma) or 2 mg specific anti-
body or pre-immune IgG bound to Protein G Sepharose
beads (GE Healthcare)) by rotating for 2 h at 48C. Protein-
bound beads were then washed twice in lysis buffer with
0.5 M NaCl, and twice in buffer A (50 mM Tris–HCl pH 7.5,
0.1 mM EGTA, 0.1% b-mercaptoethanol) at 48C. Samples
were then reduced in 50 ml of 1 SDS sample buffer (50 mM
Tris–HCl pH 6.8, 2% SDS, 10% glycerol, 0.02% bromophenol
blue, 1% b-mercaptoethanol) and boiled at 958C for 5 min.
Cell extract inputs (20 mg protein unless stated otherwise)
or IPs (40% unless stated otherwise) were resolved on 10%
denaturing SDS polyacrylamide gels and transferred onto a
nitrocellulose membrane (Whatman). Immunoblot analysis
on membranes was performed as described previously [20].
For Xenopus experiments, embryos were cultured in the
presence or absence of 10 mM cycloheximide (Sigma) in 0.1
NAM (Normal Amphibian Medium [48]) for indicated times.
Ten embryos per time point were lysed in 100 ml of
PhosphoSafe reagent (Novogen) supplemented with complete
protease inhibitor (Roche), and then extracted with an equal
volume of FREON (Sigma) to remove yolk proteins. Samples
were reduced by adding 4 SDS sample buffer (Li-Cor) with
10% b-mercaptoethanol and then boiled for 5 min. For
immunoprecipitations of xAlk3-HA, 30 embryos/condition
were lysed in PBSCA (PBS, 1% Igepal CA-630 (Sigma),
10 mg ml–1 leupeptin (Roche), 10 mg ml21 aprotinin (Roche),
1 mMN-ethylmaleimide (Sigma), 100 nM 1,10-phenanthroline
(Sigma), complete protease inhibitor (Roche)), and then
cleared by centrifugation for 20 min at 14 000g at 48C. Mouse
anti-HA (HA-7, Sigma) was added to lysates and then incu-
bated on a rotator for 2 h at 48C followed by an overnight
incubation on a rotator with 15 ml of Dynabeads Protein G
(Invitrogen) at 48C. Protein-bound beads were washed 5
with PBSCA. Samples were then reduced in 40 ml of 1 SDS
sample buffer with 2.5% b-mercaptoethanol and boiled for
5 min. Samples were separated on either 4–20% acrylamide
gels (NuSep) or 7.5% TGX gels (Bio-Rad) and then transferred
to Immobilon-FL PVDF membranes (Millipore). Membranes
were blocked for 1 h at room temperature (RT) in Li-Cor Block-
ing Buffer, and then incubated in primary antibody in PBST
(PBS, 0.1% Tween 20) overnight at 48C. Blots were washed
3 in PBST then incubated with a combination of IRDye
680LT and 800CW labelled secondary antibodies (1 : 15 000 in
PBST supplemented with 0.02% SDS) for 1 h at RT. Washed
blots were imaged with a Li-Cor Odyssey scanner followed
by image analysis using IMAGE STUDIO (Li-Cor).
5.6. Mass-spectrometric analysis
Mass-spectrometric analysis on GFP-IPs was performed by
LC–MS–MSusing a linear ion trap–orbitrap hybridmass spec-
trometer (LTQ-Orbitrap, Thermo Fisher Scientific) equipped
with a nanoelectrospray ion source (Thermo) and coupled to a
Proxeon EASY-nLC system as described previously [49].
5.7. In vitro ubiquitylation and deubiquitylation assays
For cleavage of linear, K11-, K48- and K63-linked di-
ubiquitin, 36 nM GST-USP15 was added to a 3 nM of each
ubiquitin dimer. The cleavage reactions (20 ml) were carried
out at RT in a solution containing 50 mM Tris–HCl pH 7.5,
100 mM NaCl and 5 mM DTT. Reactions were stopped at
10 or 60 min by the addition of SDS sample buffer. The clea-
vage of ubiquitin dimers was visualized by resolving
samples with SDS-PAGE and Coomassie staining the gel.
The in vivo and in vitro deubiquitylation assays of polyubiqui-
tylated ALK3 were performed as previously described [25].
In brief, in-cell deubiquitylation assays were performed in
HEK293 cells by co-transfecting FLAG-ALK3, and HA-
USP15 constructs. Prior to lysis cells were treated with
10 mM bortezomib for 3 h and FLAG was immunoprecipi-
tated. The in vitro DUB assay of in vivo polyubiquitylated
FLAG-ALK3 IPs was performed with GST-USP15 in DUB
assay buffer for 1 h at 308C on an IP-shaker. Proteins were
resolved by SDS-PAGE and immunoblotted with the
indicated antibodies.
5.8. RNAi and quantitative PCR
The siRNA and qRT-PCR primer sequences used in this
study are as follows:
All siRNAs were purchased from Sigma. Human siRNAs
targeting USP11: siUSP11 (50 –30): GAUUCUAUUGGCCUA
GUAU. Human siRNAs against USP15: siUSP15-1 (50 –30):
CUCUUGAGAAUGUGCCGAU; siUSP15-2: CACAAUAG
AUACAAUUGAA; and siUSP15-3 CACAUUGAUGGAAG
GUCAA. Control FoxO4 siRNAs (50 –30): human: CCCGAC
CAGAGAUCGCUAA, mouse: GCAAGUUCAUCAAGGU
UCA. Mouse siRNAs targeting USP15: siUSP15#1 (50 –30):
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GAACUACUGGCUUUCCUGU; #2: CCUUAUUGAUGAG
UUGGAU #3: GGUAUUGUCCAAAUUGUAA.
Human qRT-PCR primers used were as follows
GAPDH: (F,R) (ATCTTCTTTTGCGTCGCCAG, GCTGAGAC
ACCATGGGGAA)
FoxO4: (F,R) (TTGGAGAACCTGGAGTATGTGACA, AAG
CTTCCAGGCATGACTCAG)
USP11: (F,R) (GTGTTCAAGAACAAGGTTGG, CGATTAAG
GTCCTCATGCAG)
USP15: (F,R) (GACCCATTGATAACTCTGGAC, TGTTCAAC
CACCTTTCGTG)
ID1: (F,R) (AGGCTGGATGCAGTTAAGGG, GACGATCG
CATCTTGTGTCG)
SMAD6: (F, R) (CCATCAAGGTGTTCGACTTC, TTGTTGAG
GAGGATCTCCAG)
PAI1: (F, R) (AGCTCCTTGTACAGATGCCG, ACAACAGGA
GGAGAAACCCA)
The qRT-PCR reactions were performed in triplicate on an
iQ5 PCR machine (Bio-Rad) and data analysed using Micro-
soft EXCEL. All experiments have a minimum n ¼ 3. Error bars
represent the standard deviation. Statistical comparisons
( p-values) were obtained from Student’s t-test as described
previously [25].
Xenopus qRT-PCR primers used were as follows:
H4 (F,R) (CGGGATAACATTCAGGGTATCACT, ATCCA
TGGCGGTAATGTCTTCCT); xVent1 (F,R) (TTCCCTTCAGC
ATGGTTCAAC, GCATCTCCTTGGCATATTTGG). qRT-PCR
reactions were carried out on a Roche Lightcycler 480 using
LightCycler 480 SYBR Green I master mix (10 ml reactions)
according to the manufacturer’s instructions.
5.9. Alkaline phosphatase assay
C2C12 cells were transfected with siRNAs against mouse
USP15 or mouse FoxO4 (300 pM each) using transfectin
reagent and grown in DMEM with 5% FBS. Forty-eight
hours post-transfection 100 ng ml21 BMP2 was added for
2–4 days, and cells were lysed using CelLytic reagent
(Sigma). The protein concentration was determined using
Bradford and equal amounts were used to detect alkaline
phosphatase activity. Alkaline phosphatase detection was
carried out in accordance with the manufacturer’s protocol
(Sigma). In brief, cell extracts were diluted in assay buffer
and fluorescent substrate (4-methylumbelliferyl phosphate
disodium salt) was added. Fluorescence was detected using
a fluorescent plate reader (PHERAstar) at 350 nm excitation
and 460 nm emission.
5.10. Immunofluorescence
Human osteosarcoma U2OS cells transfected with FLAG-
ALK3, HA-SMAD6 and/or GFP-USP15 were seeded onto
poly-L-lysine treated glass coverslips in 6-well culture dishes.
Cells were washed in PBS before fixation with 3.7% parafor-
maldehyde for 20 min at RT. The coverslips were washed a
further three times before permeabilization with 0.2% Triton
X-100 in PBS for 15 min at RT. Cells were rinsed with PBS
before being incubated for 1 h in blocking solution (5% (v/v)
normal donkey serum, 0.01% (v/v) fish skin gelatin, 0.1%
(v/v) Triton X-100, 0.05% (v/v) Tween-20 in PBS). Primary
antibody (HA, Roche; FLAG, Sigma; GFP, Life Technologies)
incubation was done for 16 h in a humidified chamber at
48C. After thorough washes in PBS, cells were incubated with
AlexaFluor and Cyanine Cy5 (Jackson ImmunoResearch
Labs) secondary antibodies for 1 h in the dark. Cells were
washed three more times in PBS and once with deionized
water before being mounted onto glass slides using ProLong
Gold mounting reagent (Life Technologies), which contained
the nuclear stain 40,6-diamidino-2-phenylindole. Slides were
viewed using a Nikon Eclipse Ti microscope fitted with a
60 lens and a cooled charge-coupled device camera.
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